Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) Operating Expenses (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Operating Expenses data on record, last reported at $52.6 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 28.29% year-over-year to $52.6 million; the TTM value through Sep 2025 reached $215.7 million, up 62.13%, while the annual FY2024 figure was $168.9 million, 93.8% up from the prior year.
  • Operating Expenses reached $52.6 million in Q3 2025 per ZBIO's latest filing, down from $55.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $60.6 million in Q4 2024 and bottomed at $24.8 million in Q4 2023.
  • Average Operating Expenses over 3 years is $43.6 million, with a median of $44.2 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: surged 144.65% in 2024, then increased 28.29% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $24.8 million in 2023, then surged by 144.65% to $60.6 million in 2024, then decreased by 13.27% to $52.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $52.6 million in Q3 2025, $55.2 million in Q2 2025, and $47.3 million in Q1 2025.